Herceptin

Herceptin - most related articles:

- Herceptin with chemotherapy improves breast cancer survival - 6.6
- Breast cancer sufferers demand answers from PHARMAC, New Zealand - 5.3
- Math may predict Herceptin response in breast cancer patients - 5.2
- HER growth proteins do not predict outcome of herceptin treatment breast cancer patients - 5
- Inform Dual ISH to determine HER2 gene in breast cancer patients - 4.1
- SPOT-Light HER2 CISH kit approved for breast cancer patients - 3.8
- Tykerb with Herceptin increases advanced breast cancer survival - 3.5
- Lower heart effects from Herceptin breast cancer treatment with chemotherapy - 3
- Triple drug combination promising to treat breast cancer - 2.9

Herceptin articles

HER growth proteins do not predict outcome of herceptin treatment breast cancer patients
Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2 Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.

Inform Dual ISH to determine HER2 gene in breast cancer patients
Breast cancer is the second leading cause of cancer-related death among women. About 20 percent of women diagnosed with breast cancer are HER2-positive. The Inform Dual ISH test allows lab personnel to count the number of copies of HER2 genes on chromosome 17 in a small sample of the breast tumor. Copies of the HER2 gene appear black and copies of chromosome 17 appear red. Patients with more than the normal number of copies of the HER2 gene are considered candidates for Herceptin therapy.

Genomic sequencing of difficult breast cancers
Life Technologies Corporation (NASDAQ: LIFE) announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.

Tykerb with Herceptin increases advanced breast cancer survival
An investigational combination of TYKERB (lapatinib) plus HERCEPTIN (trastuzumab) proved a median survival of 14 months in women with an aggressive form of breast cancer.

Herceptin with chemotherapy improves breast cancer survival
Using Herceptin with chemotherapy clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher.

Math may predict Herceptin response in breast cancer patients
Cancer researchers are turning to mathematical models to help answer important clinical questions, and a new paper in Cancer Research, a journal of the American Association for Cancer Research, illustrates how the technique may answer questions about Herceptin resistance.

Triple drug combination promising to treat breast cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.

SPOT-Light HER2 CISH kit approved for breast cancer patients
SPOT-Light HER2 CISH kit - a novel genetic test for determining whether patients with breast cancer are good candidates for treatment with the drug Herceptin (trastuzumab) has been approved by the U.S. Food and Drug Administration.

Lower heart effects from Herceptin breast cancer treatment with chemotherapy
A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.

Breast cancer sufferers demand answers from PHARMAC, New Zealand
8 cancer survivors are in the New Zealand High Court to fight their case against drug funding agency PHARMAC. The women are challenging PHARMAC's decision not to fund 12 months of Herceptin treatment for NZ women with HER2 positive breast cancer.

Black women get breast cancer two decades earlier than white women
Black British women in Hackney, East London, are diagnosed with breast cancer 21 years younger than white British women, according to a Cancer Research UK study published online in the British Journal of Cancer.

11 Herceptin articles listed above.


Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system. Track health news daily at Health Newstrack.
Subscribe: rss | email

Top sections:
Health (188)
Breast cancer (169)
Healthcare (134)
HIV (130)
Obesity (126)
Pregnancy (115)
Diabetes (102)
Swine Flu (97)
Prostate Cancer (86)
Heart disease (85)
Smoking (81)
Alzheimer's Disease (79)
Cancer (75)
Depression (61)
Autism (53)


List health news, Health organizations, Health news world, Glossary     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2015 HealthNewstrack.com
Health Newstrack - Track Health News Daily at HealthNewstrack.com. Our Newstrack on Health News provides latest health news, medical news, and health articles with recent health & medical updates.
0.5